Cyteir Therapeutics

Cyteir Therapeutics

Cyteir Therapeutics is pioneering the treatment paradigm of gain-of-function synthetic lethality. Cyteir is developing novel molecules that inhibit Rad51-mediated homologous recombination to selectively kill cells over-expressing activation induced cytidine deaminase, AID. Cyteir is focusing on both solid and liquid tumor, as well, as auto-immune disorders like lupus, MS, etc.

<< Portfolio